What is InteloMed?
InteloMed is at the forefront of patient monitoring and informatics, developing the intelligent, multi-dimensional, non-invasive CVInsight® Patient Monitoring & Informatics System. This FDA-cleared and CE-marked system provides clinicians with unprecedented real-time, dynamic, and actionable insights into cardiovascular stress and patient tolerance during dialysis. Leveraging patented algorithms, the system offers clinician-set alerts to enable timely interventions, thereby preventing serious patient consequences. The commercial launch in the United States marks a significant milestone for the Wexford, PA-based company.
How much funding has InteloMed raised?
InteloMed has raised a total of $16.7M across 7 funding rounds:
Private Equity
$2.6M
Series A
$4M
Private Equity
$3.8M
Private Equity
$1.9M
Debt
$502K
Debt
$47K
Other Financing Round
$3.8M
Private Equity (2011): $2.6M, investors not publicly disclosed
Series A (2013): $4M, investors not publicly disclosed
Private Equity (2014): $3.8M, investors not publicly disclosed
Private Equity (2016): $1.9M, investors not publicly disclosed
Debt (2016): $502K, investors not publicly disclosed
Debt (2021): $47K with participation from PPP
Other Financing Round (2025): $3.8M, investors not publicly disclosed
What's next for InteloMed?
The recent major strategic investment signals a pivotal growth phase for InteloMed. This capital infusion is expected to accelerate the commercial expansion of the CVInsight® system and further enhance its capabilities. The company's focus on providing critical, non-invasive patient monitoring data positions it for substantial impact within the healthcare informatics sector. Future developments will likely concentrate on broadening market penetration and potentially exploring new applications for its proprietary technology.
See full InteloMed company page
